These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 8656262)
1. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. Colonna P; Jais JP; Desablens B; Harousseau JL; Brière J; Boasson M; Lemevel A; Casassus P; Le Prisé PY; Guilhot F; Ghandour C; Lejeune F; Andrieu JM J Clin Oncol; 1996 Jun; 14(6):1928-35. PubMed ID: 8656262 [TBL] [Abstract][Full Text] [Related]
2. Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages. Andrieu JM; Jais JP; Colonna P; Desablens B; Brière J; François S; Harousseau JL; Casassus P; Lemevel A; Le Prisé PY; Ghandour C; Guilhot F; Lejeune F Ann Oncol; 1998 Feb; 9(2):195-203. PubMed ID: 9553666 [TBL] [Abstract][Full Text] [Related]
3. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD. Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040 [TBL] [Abstract][Full Text] [Related]
4. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863 [TBL] [Abstract][Full Text] [Related]
5. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. Elconin JH; Roberts KB; Rizzieri DA; Vermont C; Clough RW; Kim C; Dodge RK; Prosnitz LR Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1097-105. PubMed ID: 11072168 [TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial. Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171 [TBL] [Abstract][Full Text] [Related]
7. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M; Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834 [TBL] [Abstract][Full Text] [Related]
8. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study. Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162 [TBL] [Abstract][Full Text] [Related]
9. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy. Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642 [TBL] [Abstract][Full Text] [Related]
10. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy). De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457 [TBL] [Abstract][Full Text] [Related]
11. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381 [TBL] [Abstract][Full Text] [Related]
12. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG). Diehl V; Loeffler M; Pfreundschuh M; Ruehl U; Hasenclever D; Nisters-Backes H; Sieber M; Smith K; Tesch H; Geilen W Ann Oncol; 1995 Nov; 6(9):901-10. PubMed ID: 8624293 [TBL] [Abstract][Full Text] [Related]
13. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055 [TBL] [Abstract][Full Text] [Related]
14. Hodgkin's disease, clinical stages I, II A-B and IIIA. Results of brief chemotherapy followed by irradiation. Fermé C; Lepage E; D'Agay MF; Brice P; Castaigne S; Fermand JP; Frija J; Miot C; Brouet JC; Marty M Nouv Rev Fr Hematol (1978); 1992; 34(3):247-55. PubMed ID: 1383924 [TBL] [Abstract][Full Text] [Related]
15. Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. Preti A; Hagemeister FB; McLaughlin P; Swan F; Rodriguez A; Besa P; Cox JD; Allen PK; Cabanillas F Ann Oncol; 1994; 5 Suppl 2():97-100. PubMed ID: 7515653 [TBL] [Abstract][Full Text] [Related]
16. Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy. Karmiris TD; Grigoriou E; Tsantekidou M; Spanou E; Mihalakeas H; Baltadakis J; Apostolidis J; Pagoni M; Karakasis D; Bakiri M; Mitsouli C; Harhalakis N; Nikiforakis E Leuk Lymphoma; 2003 Sep; 44(9):1523-8. PubMed ID: 14565654 [TBL] [Abstract][Full Text] [Related]
17. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Carde P; Hagenbeek A; Hayat M; Monconduit M; Thomas J; Burgers MJ; Noordijk EM; Tanguy A; Meerwaldt JH; Le Fur R J Clin Oncol; 1993 Nov; 11(11):2258-72. PubMed ID: 7693881 [TBL] [Abstract][Full Text] [Related]
18. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M; J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Diehl V; Pfreundschuh M; Löffler M; Rühl U; Hiller E; Gerhartz H; Wilmanns W; Kirchner H; Schoppe W; Petsch S Med Oncol Tumor Pharmacother; 1989; 6(2):155-62. PubMed ID: 2473363 [TBL] [Abstract][Full Text] [Related]
20. Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stage I, II and IIIA). André M; Brice P; Cazals D; Hennequin C; Fermé C; Kerneis Y; Rousselot P; Zini JM; Lepage E; Gisselbrecht C Hematol Cell Ther; 1997 Apr; 39(2):59-65. PubMed ID: 9168301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]